Literature DB >> 35190513

Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes.

Alec W R Langlois1,2, Ahmed El-Boraie1,2, Koya Fukunaga3, Taisei Mushiroda3, Michiaki Kubo3, Caryn Lerman4, Jo Knight5,6, Steven E Scherer7, Meghan J Chenoweth1,2, Rachel F Tyndale1,2,6.   

Abstract

OBJECTIVES: We evaluated multiple genotyping/sequencing approaches in a homologous region of chromosome 19, and investigated associations of two common 3'-UTR CYP2A6 variants with activity in vivo.
METHODS: Individuals (n = 1704) of European and African ancestry were phenotyped for the nicotine metabolite ratio (NMR), an index of CYP2A6 activity, and genotyped/sequenced using deep amplicon exon sequencing, SNP array, genotype imputation and targeted capture sequencing. Amplicon exon sequencing was the gold standard to which other methods were compared within-individual for CYP2A6, CYP2A7, CYP2A13, and CYP2B6 exons to identify highly discordant positions. Linear regression models evaluated the association of CYP2A6*1B and rs8192733 genotypes (coded additively) with logNMR.
RESULTS: All approaches were ≤2.6% discordant with the gold standard; discordant calls were concentrated at few positions. Fifteen positions were discordant in >10% of individuals, with 12 appearing in regions of high identity between homologous genes (e.g. CYP2A6 and CYP2A7). For six, allele frequencies in our study and online databases were discrepant, suggesting errors in online sources. In the European-ancestry group (n = 935), CYP2A6*1B and rs8192733 were associated with logNMR (P < 0.001). A combined model found main effects of both variants on increasing logNMR. Similar trends were found in those of African ancestry (n = 506).
CONCLUSION: Multiple genotyping/sequencing approaches used in this chromosome 19 region contain genotyping/sequencing errors, as do online databases. Gene-specific primers and SNP array probes must consider gene homology; short-read sequencing of related genes in a single reaction should be avoided. Using improved sequencing approaches, we characterized two gain-of-function 3'-UTR variants, including the relatively understudied rs8192733.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35190513      PMCID: PMC9081136          DOI: 10.1097/FPC.0000000000000466

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.000


  39 in total

1.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

2.  Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.

Authors:  Jill C Mwenifumbo; Nael Al Koudsi; Man Ki Ho; Qian Zhou; Ewa B Hoffmann; Edward M Sellers; Rachel F Tyndale
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

3.  Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.

Authors:  Caryn Lerman; Robert A Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; E Paul Wileyto; Gary E Swan; Neal L Benowitz; Daniel F Heitjan; Rachel F Tyndale
Journal:  Lancet Respir Med       Date:  2015-01-12       Impact factor: 30.700

4.  Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Authors:  Julie-Anne Tanner; Andy Z Zhu; Katrina G Claw; Bhagwat Prasad; Viktoriya Korchina; Jianhong Hu; HarshaVardhan Doddapaneni; Donna M Muzny; Erin G Schuetz; Caryn Lerman; Kenneth E Thummel; Steven E Scherer; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2018-01       Impact factor: 2.089

5.  Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.

Authors:  Meghan J Chenoweth; Jennifer J Ware; Andy Z X Zhu; Christopher B Cole; Lisa Sanderson Cox; Nikki Nollen; Jasjit S Ahluwalia; Neal L Benowitz; Robert A Schnoll; Larry W Hawk; Paul M Cinciripini; Tony P George; Caryn Lerman; Joanne Knight; Rachel F Tyndale
Journal:  Addiction       Date:  2017-11-02       Impact factor: 6.526

6.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

7.  Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.

Authors:  M K Ho; J C Mwenifumbo; N Al Koudsi; K S Okuyemi; J S Ahluwalia; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2009-03-11       Impact factor: 6.875

8.  Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.

Authors:  Meghan J Chenoweth; Maria Novalen; Larry W Hawk; Robert A Schnoll; Tony P George; Paul M Cinciripini; Caryn Lerman; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-10       Impact factor: 4.254

9.  Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.

Authors:  J C Mwenifumbo; C N Lessov-Schlaggar; Q Zhou; R E Krasnow; G E Swan; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2007-05-23       Impact factor: 6.875

10.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.